Abstract
This is a case report of a 62-year-old male patient diagnosed with an anaplastic astrocytoma WHO III, which was treated with anti-angiogenic therapy upon recurrence and further on developed gliomatosis cerebri. This case report demonstrates that during the course of anti-angiogenic therapy conventional MacDonalds MRI criteria are insufficient to assess tumour response. Advanced MRI sequences with MR-perfusion should be incorporated for response evaluation. 18F-FET-PET imaging may be an additional valuable tool to detect early tumour progression. At present, the value of such advanced imaging techniques is prospectively studied within the "AVIRMA trial" for patients with recurrent malignant glioma treated by Bevacizumab/Irinotecan.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
